Der er ikke rapporteret om teratogen risiko efter kontrolleret ovarie hyperstimulation under klinisk anvendelse af gonadotropiner.
No teratogenic risk has been reported, following controlled ovarian hyperstimulation, in clinical use with gonadotropins.